Improvement of psychic and somatic symptoms in adult patients with generalized anxiety disorder: examination from a duloxetine, venlafaxine extended-release and placebo-controlled trial
The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
Background: This study examined the efficacy and tolerability of duloxetine and venlafaxine extended-release (XR) treatment for generalized anxiety disorder (GAD), with a secondary focus on psychic and somatic symptoms within GAD. Method: The design was a 10-week, multi-center, double-blind placebo-controlled study of duloxetine (20 mg or 60–120 mg once daily) and venlafaxine XR (75–225 mg once daily) treatment. Efficacy was measured using the Hamilton Anxiety Rating Scale (HAMA), which includes psychic and somatic factor scores. Tolerability was measured by occurrence of treatment-emergent adverse events (TEAEs) and discontinuation rates. Results: Adult out-patients (mean age 42.8 years; 57.1% women) with DSM-IV-defined GAD were randomly assigned to placebo (n=170), duloxetine 20 mg (n=84), duloxetine 60–120 mg (n=158) or venlafaxine XR 75–225 mg (n=169) treatment. Each of the three active treatment groups had significantly greater improvements on HAMA total score from baseline to endpoint compared with placebo (p=0.01–0.001). For the HAMA psychic factor score, both duloxetine treatment arms and venlafaxine XR demonstrated significantly greater improvement compared with placebo (p=0.01–0.001). For the HAMA somatic factor score, the mean improvement in the duloxetine 60–120 mg and venlafaxine XR groups was significantly greater than placebo (p⩽0.05 and p⩽0.01 respectively), whose mean improvement did not differ from the duloxetine 20 mg group (p=0.07). Groups did not differ in study discontinuation rate due to adverse events. Conclusions: Duloxetine and venlafaxine treatment were each efficacious for improvement of core psychic anxiety symptoms and associated somatic symptoms for adults with GAD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Estimation of a Single Effect Size: Parametric and Nonparametric Methods
Hedges, L. V., & Olkin, I. (1985) · Statistical Methods for Meta-Analysis · doi:10.1016/b978-0-08-057065-5.50010-5 · Cited by 983
Shear, M. K., Vander Bilt, J., Rucci, P., Endicott, J., Lydiard, B., Otto, M. W., Pollack, M. H., Chandler, L., Williams, J., Ali, A., et al. (2001) · Depression and Anxiety · doi:10.1002/da.1033 · Cited by 483
Papakostas, G. I., Thase, M. E., Fava, M., Nelson, J. C., & Shelton, R. C. (2007) · Biological Psychiatry · doi:10.1016/j.biopsych.2007.03.027 · Cited by 308 · cited 1×
“…studies have begun to suggest that SNRIs may have a slight incremental benefit compared with selective serotonergic reuptake inhibitors (Papakostas et al. 2007) for MDD, further studies are needed to determine whether the potentiation of both serotonin and norepinephrine rather than…”
BackgroundExperience and appraisal of worry among high worriers with and without generalized anxiety disorder
Ruscio, A. M., & Borkovec, T. D. (2004) · Behaviour Research and Therapy · doi:10.1016/j.brat.2003.10.007 · Cited by 222
Becker, E. S., Goodwin, R., Hölting, C., Hoyer, J., & Margraf, J. (2003) · Journal of Nervous & Mental Disease · doi:10.1097/01.nmd.0000092198.20420.fc · Cited by 31 · cited 1×
“The content of worry may vary across patients with GAD, but often involves everyday, routine life circumstances (job responsibilities, finances, being late), and health concerns for self or other family members (Becker et al. 2003).”
BackgroundThe rater applied performance scale: development and reliability
Lipsitz, J., Kobak, K., Feiger, A., Sikich, D., Moroz, G., & Engelhard, A. (2004) · Psychiatry Research · doi:10.1016/j.psychres.2004.03.001 · Cited by 31 · cited 2×
“The Rater Applied Performance Scale : development and reliability.”
Method
Cited by
Efficacy of drug treatments for generalised anxiety disorder: systematic review and meta-analysis
Baldwin, D., Woods, R., Lawson, R., & Taylor, D. (2011) · BMJ · doi:10.1136/bmj.d1199 · Cited by 285
Pharmacotherapy of anxiety disorders: A critical review
Koen, N., & Stein, D. J. (2011) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2011.13.4/nkoen · Cited by 151
Systematic review and meta-analysis: dose-response curve of SSRIs and SNRIs in anxiety disorders
Jakubovski, E., Johnson, J. A., Nasir, M., Müller-Vahl, K., & Bloch, M. H. (2019) · Depression and Anxiety · doi:10.1002/da.22854 · Cited by 131
Gomez, A. F., Barthel, A. L., & Hofmann, S. G. (2018) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2018.1472767 · Cited by 125
Hoertel, N., Le Strat, Y., Blanco, C., Lavaud, P., & Dubertret, C. (2012) · Depression and Anxiety · doi:10.1002/da.21937 · Cited by 61
Comprehensive review of generalized anxiety disorder in primary care in Europe.
Parmentier, H., García-Campayo, J., & Prieto, R. (2013) · Current Medical Research and Opinion · doi:10.1185/03007995.2013.770731 · Cited by 37
Antidepressants versus placebo for generalised anxiety disorder (GAD)
Kopcalic, K., Arcaro, J., Pinto, A., Ali, S., Barbui, C., Curatoli, C., Martin, J., & Guaiana, G. (2025) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd012942.pub2 · Cited by 16
Metadata
- Authors
- Nicolini, H., Bakish, D., Duenas, H., Spann, M., Erickson, J., Hallberg, C., Ball, S., Sagman, D., & Russell, J. M.
- Venue
- Psychological Medicine
- Publisher
- Cambridge University Press (CUP)
- Published
- 2008-05-19
- Volume
- 39
- Issue
- 2
- Pages
- 267-276
- ISSN
- 0033-2917 (ISSN-L)
- 1469-8978
- OpenAlex
- W2105710387
- Cited by
- 66
- References
- 6
- FWCI
- 10.86
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.